BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmia in the general population. Cardiac troponin I (cTnI) can be elevated in patients with AF without coexisting coronary artery disease (CAD). The aim of this study was to characterize the diagnostic accuracy and clinical usefulness of a cTnI assay for the diagnosis of CAD in patients with AF. METHODS: Patients with AF undergoing coronary angiography were included in the study. The workflow chart encompassed measuring of cTnI in all patients at admission and after 6 h. RESULTS: Patients with CAD were older (73.8 ± 7.6 vs. 65.3 ± 12.9 years) than patients without CAD; for all other characteristics, no significant differences were observed. Of the patients, 39 had CAD [12 patients one-vessel disease (VD), 14 patients 2-VD, 13 patients 3-VD] and 16 patients had acute myocardial infarction and were undergoing percutaneous coronary intervention. There was no significant difference in cTnI concentrations between patients without and with CAD at admission (0.02 vs. 0.03 ng/ml, respectively); however, a difference was noted after 6 h (0.03 vs. 0.06 ng/ml, respectively). CONCLUSION: AF patients both without and with CAD showed similar cTnI concentrations at admission. A second validation of cTnI is mandatory for all patients.
BACKGROUND:Atrial fibrillation (AF) is the most common arrhythmia in the general population. Cardiac troponin I (cTnI) can be elevated in patients with AF without coexisting coronary artery disease (CAD). The aim of this study was to characterize the diagnostic accuracy and clinical usefulness of a cTnI assay for the diagnosis of CAD in patients with AF. METHODS:Patients with AF undergoing coronary angiography were included in the study. The workflow chart encompassed measuring of cTnI in all patients at admission and after 6 h. RESULTS:Patients with CAD were older (73.8 ± 7.6 vs. 65.3 ± 12.9 years) than patients without CAD; for all other characteristics, no significant differences were observed. Of the patients, 39 had CAD [12 patients one-vessel disease (VD), 14 patients 2-VD, 13 patients 3-VD] and 16 patients had acute myocardial infarction and were undergoing percutaneous coronary intervention. There was no significant difference in cTnI concentrations between patients without and with CAD at admission (0.02 vs. 0.03 ng/ml, respectively); however, a difference was noted after 6 h (0.03 vs. 0.06 ng/ml, respectively). CONCLUSION:AFpatients both without and with CAD showed similar cTnI concentrations at admission. A second validation of cTnI is mandatory for all patients.
Authors: S S Rathore; A K Berger; K P Weinfurt; K A Schulman; W J Oetgen; B J Gersh; A J Solomon Journal: Circulation Date: 2000-03-07 Impact factor: 29.690
Authors: Marc Bonaca; Benjamin Scirica; Marc Sabatine; Anthony Dalby; Jindrich Spinar; Sabina A Murphy; Peter Jarolim; Eugene Braunwald; David A Morrow Journal: J Am Coll Cardiol Date: 2010-05-11 Impact factor: 24.094
Authors: Torbjørn Omland; Marc A Pfeffer; Scott D Solomon; James A de Lemos; Helge Røsjø; Jūratė Šaltytė Benth; Aldo Maggioni; Michael J Domanski; Jean L Rouleau; Marc S Sabatine; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2013-02-13 Impact factor: 24.094